Tags : Palvella Therapeutics


Ligand Purchases Palvella’s Royalty Rights and Milestone Payments of PTX-022

Shots: Palvella will receive $10M as total deal value from Ligand, and will be responsible for PTX-022 development and commercialization. Ligand to get milestones and royalties on sales of PTX-022 The focus of the agreement is to develop PTX-022 for its approval, with its expected launch in 2022. In Nov, 2018 PTX-022 has received FDA’s ODD and Fast Track […]Read More